StreetInsider.com News Articles

Journey Medical Corporation to Participate in September 2026 Investor Conferences

Tue, 08 Sep 2026 16:05:00 -0400

SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences.

Details of the events are as follows:

Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference
Date: Thursday, September 10, 2026
Location: New York City
Format: 1x1 Meetings

H.C. Wainwright

Journey Medical Corporation to Participate in September 2026 Investor Conferences

Tue, 08 Sep 2026 16:05:00 -0400

SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences.

Details of the events are as follows:

Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference
Date: Thursday, September 10, 2026
Location: New York City
Format: 1x1 Meetings

H.C. Wainwright

Journey Medical Corporation to Participate in September 2026 Investor Conferences

Tue, 08 Sep 2026 16:05:00 -0400

SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences.

Details of the events are as follows:

Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference
Date: Thursday, September 10, 2026
Location: New York City
Format: 1x1 Meetings

H.C. Wainwright

Journey Medical Corporation to Participate in September 2026 Investor Conferences

Tue, 08 Sep 2026 16:05:00 -0400

SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences.

Details of the events are as follows:

Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference
Date: Thursday, September 10, 2026
Location: New York City
Format: 1x1 Meetings

H.C. Wainwright

Longeveron names Nirav Jhaveri as CFO

Wed, 19 Aug 2026 16:05:16 -0400

Longeveron Inc. (NASDAQ: LGVN) has appointed Nirav Jhaveri as chief financial officer, principal financial officer, and principal accounting officer, according to a company statement.

Jhaveri succeeds Marie Washburn, who had served as interim CFO following the retirement of the prior CFO. Washburn will return to her role as corporate controller.

Jhaveri holds more than 25 years of experience in capital markets, corporate finance, business development, and investor relations, including over 15 years in the biotech sector. He previously served as CFO at Opus Genetics (NASDAQ: IRD), Insilico Medicine (HKEX: 3696.HK), and Journey Medical Corporation (NASDAQ: DERM). Earlier in his career, he held

Longeveron names Nirav Jhaveri as CFO

Wed, 19 Aug 2026 16:05:16 -0400

Longeveron Inc. (NASDAQ: LGVN) has appointed Nirav Jhaveri as chief financial officer, principal financial officer, and principal accounting officer, according to a company statement.

Jhaveri succeeds Marie Washburn, who had served as interim CFO following the retirement of the prior CFO. Washburn will return to her role as corporate controller.

Jhaveri holds more than 25 years of experience in capital markets, corporate finance, business development, and investor relations, including over 15 years in the biotech sector. He previously served as CFO at Opus Genetics (NASDAQ: IRD), Insilico Medicine (HKEX: 3696.HK), and Journey Medical Corporation (NASDAQ: DERM). Earlier in his career, he held

Longeveron names Nirav Jhaveri as CFO

Wed, 19 Aug 2026 16:05:16 -0400

Longeveron Inc. (NASDAQ: LGVN) has appointed Nirav Jhaveri as chief financial officer, principal financial officer, and principal accounting officer, according to a company statement.

Jhaveri succeeds Marie Washburn, who had served as interim CFO following the retirement of the prior CFO. Washburn will return to her role as corporate controller.

Jhaveri holds more than 25 years of experience in capital markets, corporate finance, business development, and investor relations, including over 15 years in the biotech sector. He previously served as CFO at Opus Genetics (NASDAQ: IRD), Insilico Medicine (HKEX: 3696.HK), and Journey Medical Corporation (NASDAQ: DERM). Earlier in his career, he held

Longeveron names Nirav Jhaveri as CFO

Wed, 19 Aug 2026 16:05:16 -0400

Longeveron Inc. (NASDAQ: LGVN) has appointed Nirav Jhaveri as chief financial officer, principal financial officer, and principal accounting officer, according to a company statement.

Jhaveri succeeds Marie Washburn, who had served as interim CFO following the retirement of the prior CFO. Washburn will return to her role as corporate controller.

Jhaveri holds more than 25 years of experience in capital markets, corporate finance, business development, and investor relations, including over 15 years in the biotech sector. He previously served as CFO at Opus Genetics (NASDAQ: IRD), Insilico Medicine (HKEX: 3696.HK), and Journey Medical Corporation (NASDAQ: DERM). Earlier in his career, he held

Longeveron names Nirav Jhaveri as CFO

Wed, 19 Aug 2026 16:05:16 -0400

Longeveron Inc. (NASDAQ: LGVN) has appointed Nirav Jhaveri as chief financial officer, principal financial officer, and principal accounting officer, according to a company statement.

Jhaveri succeeds Marie Washburn, who had served as interim CFO following the retirement of the prior CFO. Washburn will return to her role as corporate controller.

Jhaveri holds more than 25 years of experience in capital markets, corporate finance, business development, and investor relations, including over 15 years in the biotech sector. He previously served as CFO at Opus Genetics (NASDAQ: IRD), Insilico Medicine (HKEX: 3696.HK), and Journey Medical Corporation (NASDAQ: DERM). Earlier in his career, he held

Longeveron names Nirav Jhaveri as CFO

Wed, 19 Aug 2026 16:05:16 -0400

Longeveron Inc. (NASDAQ: LGVN) has appointed Nirav Jhaveri as chief financial officer, principal financial officer, and principal accounting officer, according to a company statement.

Jhaveri succeeds Marie Washburn, who had served as interim CFO following the retirement of the prior CFO. Washburn will return to her role as corporate controller.

Jhaveri holds more than 25 years of experience in capital markets, corporate finance, business development, and investor relations, including over 15 years in the biotech sector. He previously served as CFO at Opus Genetics (NASDAQ: IRD), Insilico Medicine (HKEX: 3696.HK), and Journey Medical Corporation (NASDAQ: DERM). Earlier in his career, he held

Longeveron names Nirav Jhaveri as CFO

Wed, 19 Aug 2026 16:05:16 -0400

Longeveron Inc. (NASDAQ: LGVN) has appointed Nirav Jhaveri as chief financial officer, principal financial officer, and principal accounting officer, according to a company statement.

Jhaveri succeeds Marie Washburn, who had served as interim CFO following the retirement of the prior CFO. Washburn will return to her role as corporate controller.

Jhaveri holds more than 25 years of experience in capital markets, corporate finance, business development, and investor relations, including over 15 years in the biotech sector. He previously served as CFO at Opus Genetics (NASDAQ: IRD), Insilico Medicine (HKEX: 3696.HK), and Journey Medical Corporation (NASDAQ: DERM). Earlier in his career, he held

Longeveron names Nirav Jhaveri as CFO

Wed, 19 Aug 2026 16:05:16 -0400

Longeveron Inc. (NASDAQ: LGVN) has appointed Nirav Jhaveri as chief financial officer, principal financial officer, and principal accounting officer, according to a company statement.

Jhaveri succeeds Marie Washburn, who had served as interim CFO following the retirement of the prior CFO. Washburn will return to her role as corporate controller.

Jhaveri holds more than 25 years of experience in capital markets, corporate finance, business development, and investor relations, including over 15 years in the biotech sector. He previously served as CFO at Opus Genetics (NASDAQ: IRD), Insilico Medicine (HKEX: 3696.HK), and Journey Medical Corporation (NASDAQ: DERM). Earlier in his career, he held

Longeveron names Nirav Jhaveri as CFO

Wed, 19 Aug 2026 16:05:16 -0400

Longeveron Inc. (NASDAQ: LGVN) has appointed Nirav Jhaveri as chief financial officer, principal financial officer, and principal accounting officer, according to a company statement.

Jhaveri succeeds Marie Washburn, who had served as interim CFO following the retirement of the prior CFO. Washburn will return to her role as corporate controller.

Jhaveri holds more than 25 years of experience in capital markets, corporate finance, business development, and investor relations, including over 15 years in the biotech sector. He previously served as CFO at Opus Genetics (NASDAQ: IRD), Insilico Medicine (HKEX: 3696.HK), and Journey Medical Corporation (NASDAQ: DERM). Earlier in his career, he held

Longeveron names Nirav Jhaveri as CFO

Wed, 19 Aug 2026 16:05:16 -0400

Longeveron Inc. (NASDAQ: LGVN) has appointed Nirav Jhaveri as chief financial officer, principal financial officer, and principal accounting officer, according to a company statement.

Jhaveri succeeds Marie Washburn, who had served as interim CFO following the retirement of the prior CFO. Washburn will return to her role as corporate controller.

Jhaveri holds more than 25 years of experience in capital markets, corporate finance, business development, and investor relations, including over 15 years in the biotech sector. He previously served as CFO at Opus Genetics (NASDAQ: IRD), Insilico Medicine (HKEX: 3696.HK), and Journey Medical Corporation (NASDAQ: DERM). Earlier in his career, he held

Longeveron names Nirav Jhaveri as CFO

Wed, 19 Aug 2026 16:05:16 -0400

Longeveron Inc. (NASDAQ: LGVN) has appointed Nirav Jhaveri as chief financial officer, principal financial officer, and principal accounting officer, according to a company statement.

Jhaveri succeeds Marie Washburn, who had served as interim CFO following the retirement of the prior CFO. Washburn will return to her role as corporate controller.

Jhaveri holds more than 25 years of experience in capital markets, corporate finance, business development, and investor relations, including over 15 years in the biotech sector. He previously served as CFO at Opus Genetics (NASDAQ: IRD), Insilico Medicine (HKEX: 3696.HK), and Journey Medical Corporation (NASDAQ: DERM). Earlier in his career, he held

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Wed, 19 Aug 2026 16:05:00 -0400

Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector

MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company’s executive leadership team in the role of Chief Financial Officer (“CFO”), principal financial officer and principal accounting officer. He succeeds Marie Washburn who stepped

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Wed, 19 Aug 2026 16:05:00 -0400

Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector

MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company’s executive leadership team in the role of Chief Financial Officer (“CFO”), principal financial officer and principal accounting officer. He succeeds Marie Washburn who stepped

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Wed, 19 Aug 2026 16:05:00 -0400

Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector

MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company’s executive leadership team in the role of Chief Financial Officer (“CFO”), principal financial officer and principal accounting officer. He succeeds Marie Washburn who stepped

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Wed, 19 Aug 2026 16:05:00 -0400

Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector

MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company’s executive leadership team in the role of Chief Financial Officer (“CFO”), principal financial officer and principal accounting officer. He succeeds Marie Washburn who stepped

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Wed, 19 Aug 2026 16:05:00 -0400

Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector

MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company’s executive leadership team in the role of Chief Financial Officer (“CFO”), principal financial officer and principal accounting officer. He succeeds Marie Washburn who stepped

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Wed, 19 Aug 2026 16:05:00 -0400

Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector

MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company’s executive leadership team in the role of Chief Financial Officer (“CFO”), principal financial officer and principal accounting officer. He succeeds Marie Washburn who stepped

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Wed, 19 Aug 2026 16:05:00 -0400

Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector

MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company’s executive leadership team in the role of Chief Financial Officer (“CFO”), principal financial officer and principal accounting officer. He succeeds Marie Washburn who stepped

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Wed, 19 Aug 2026 16:05:00 -0400

Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector

MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company’s executive leadership team in the role of Chief Financial Officer (“CFO”), principal financial officer and principal accounting officer. He succeeds Marie Washburn who stepped

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Wed, 19 Aug 2026 16:05:00 -0400

Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector

MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company’s executive leadership team in the role of Chief Financial Officer (“CFO”), principal financial officer and principal accounting officer. He succeeds Marie Washburn who stepped

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Wed, 19 Aug 2026 16:05:00 -0400

Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector

MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company’s executive leadership team in the role of Chief Financial Officer (“CFO”), principal financial officer and principal accounting officer. He succeeds Marie Washburn who stepped